Literature DB >> 16564167

Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer.

Eduard Ryschich1, Angela Märten, Eduard Schmidt, Michael Linnebacher, Nicolas Wentzensen, Sven Eisold, Ernst Klar, Markus W Büchler, Jan Schmidt.   

Abstract

The aim of this study was to investigate the effects of an activating anti-CD40 antibody (aCD40Ab) on leukocyte adhesion to tumour vessels, leukocyte migration and tumour growth in experimental liver cancer. Morris-Hepatoma was induced by subcapsular inoculation of tumour cells in the liver of ACI-rats. On day 7 and 8 after tumour cell injection, one group of the animals received aCD40Ab. On day 13 the tumour volume was measured and intravital microscopy was performed quantifying leukocyte adherence in the liver. Furthermore, immunohistological analyses were performed. aCD40Ab-Treated animals showed increased leukocyte-endothelium interaction, demonstrated substantially more T- and natural killer (NK) cells in the tumour and had a distinctly decreased tumour volume. Our results show that treatment with aCD40Ab stimulates endothelial leukocyte adhesion in tumour vessels and migration of CD4 cells/CD8 T-cells and NK cells into the tumour and inhibits tumour growth. Thus, the CD40/CD154 pathway is a worthwhile target for adjuvant immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16564167     DOI: 10.1016/j.ejca.2006.01.024

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis.

Authors:  Elizabeth Sitati; Erin E McCandless; Robyn S Klein; Michael S Diamond
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

2.  Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1/2 signaling pathway.

Authors:  Yan Guo; Ji Ma; Lin Wu; Qianrong Wang; Xia Li; Xiaoming Li; Yuan Zhang; Jian Zhang; Libo Yao; Jing Zhang; Wenchao Liu
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

3.  Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine.

Authors:  Yan Guo; Xi'an Li; Xiang Sun; Jiancai Wang; Xu Yang; Xin Zhou; Xinping Liu; Wenchao Liu; Jianlin Yuan; Libo Yao; Xia Li; Lan Shen
Journal:  Int J Biol Sci       Date:  2019-07-03       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.